Cancer Monoclonal Antibody Partnering Terms and Agreements -- NEW YORK, Nov. 21, 2013 /PRNewswire/ -- Cancer Monoclonal Antibody Partnering Terms and Agreements The Cancer Monoclonal Antibody Partnering Agreements report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in cancer monoclonal antibody partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Cancer monoclonal antibody partnering contract documents Top cancer monoclonal antibody deals by value The report provides an understanding and analysis of how and why companies enter cancer monoclonal antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes antibody-drug conjugate deals and alliances. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This report contains over 350 links to online copies of actual cancer monoclonal antibody deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. The initial chapters of this report provide an orientation of cancer monoclonal antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in cancer monoclonal antibody dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms. Chapter 3 provides a review of the leading cancer monoclonal antibody deals since 2007. Deals are listed by headline value, signed by big pharma, big biotech and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with deal announcement in cancer monoclonal antibody partnering, with a brief summary followed by a comprehensive listing of cancer monoclonal antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. Chapter 5 provides a comprehensive listing of the top 50 big biotech companies with deal announcement in cancer monoclonal antibody partnering,with a brief summary followed by a comprehensive listing of cancer monoclonal antibody deals, as well as contract documents available in the public domain. Chapter 6 provides a comprehensive and detailed review of cancer monoclonal antibody partnering deals signed and announced since January 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy focus, and monoclonal antibody technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in cancer monoclonal antibody partnering and dealmaking since 2007. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of cancer monoclonal antibody technologies and products. Report scope Cancer Monoclonal Antibody Partnering Agreements is intended to provide the reader with an in-depth understanding and access to cancer monoclonal antibody trends and structure of deals entered into by leading companies worldwide. Cancer Monoclonal Antibody Partnering Agreements includes: Trends in cancer monoclonal antibody dealmaking in the biopharma industry since 2007 Analysis of cancer monoclonal antibody deal structure Access to headline, upfront, milestone and royalty data Access to over 350 cancer monoclonal antibody deal records The leading cancer monoclonal antibody deals by value since 2007 In Cancer Monoclonal Antibody Partnering Agreements, the available deals are listed by: Company A-Z Headline value Stage of development at signing Deal component type Specific oncology therapy target Monoclonal antibody type The Cancer Monoclonal Antibody Partnering Agreements report provides comprehensive access to available deals and contract documents for over 350 cancer monoclonal antibody deals. Analyzing actual contract agreements allows assessment of the following: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How aresales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Cancer Monoclonal Antibody Partnering Agreements provides the reader with the following key benefits: In-depth understanding of cancer monoclonal antibody deal trends since 2007 Access to headline, upfront, milestone and royalty data Acces to the structure of cancer monoclonal antibody agreements with numerous real life case studies Comprehensive access to over 350 actual cancer monoclonal antibody deals entered into by the world's biopharma companies Insight into the terms included in a cancer monoclonal antibody agreement, together with real world clause examples Understand the key deal terms companies have agreed in previous deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies Chapter 1 - Introduction Chapter 2 - Trends in cancer monoclonal antibody dealmaking Introduction 2.2. Cancer monoclonal antibody partnering over the years 2.3. Big pharma cancer monoclonal antibody dealmaking activity 2.4. Big biotech cancer monoclonal antibody dealmaking activity 2.5. Most active in cancer monoclonal antibody partnering 2.6. Cancer monoclonal antibody partnering by deal type 2.7. Cancer monoclonal antibody partnering by stage of development 2.8. Cancer monoclonal antibody partnering by cancer indication 2.9. Cancer monoclonal antibody partnering by antibody type 2.10. Disclosed deal terms for cancer monoclonal antibody partnering 2.10.1 Cancer monoclonal antibody partnering headline values 2.10.2 Cancer monoclonal antibody deal upfront payments 2.10.3 Cancer monoclonal antibody deal milestone payments 2.10.4 Cancer monoclonal antibody royalty rates Chapter 3 - Leading cancer monoclonal antibody deals Introduction 3.2. Top cancer monoclonal antibody deals by value Chapter 4 - Big pharma cancer monoclonal antibody deals Introduction 4.2. How to use big pharma partnering deals 4.3. Big pharma cancer monoclonal antibody partnering company profiles Abbott Actavis Amgen Astellas AstraZeneca Bayer Biogen Idec Boehringer Ingelheim Bristol-Myers Squibb Celgene CSL Daiichi Sankyo Eli Lilly Fresenius Gilead Sciences GlaxoSmithKline Johnson & Johnson Janssen Biotech Janssen Pharmaceutica NV Menarini Merck & Co Merck KGaA Novartis Novo Nordisk Otsuka Pfizer Roche Sanofi Sanofi-Aventis Servier Takeda Teva UCB Chapter 5 - Big biotech cancer monoclonal antibody deals Introduction 5.2. How to use big biotech partnering deals 5.3. Big biotech cancer monoclonal antibody partnering company profiles Alexion Pharmaceuticals Biocon Emergent BioSolutions Genmab LFB Group Morphosys Novo Nordisk PDL BioPharma Seattle Genetics Spectrum Pharmaceuticals Swedish Orphan Biovitrum Chapter 6 - Cancer monoclonalantibody dealmaking directory Introduction 6.2. Company A-Z 6.3. By stage of development Discovery Formulation Marketed Phase I Phase II Phase III Preclinical Regulatory 6.4. By deal type Asset purchase Assignment Bigpharma outlicensing Co-development Collaborative R&D Co-market Contract service Co-promotion CRADA Cross-licensing Development Distribution Equity purchase Evaluation Grant Joint venture Licensing Loan Manufacturing Marketing Material transfer Option Promotion Research Settlement Spin out Sub-license Supply Technology transfer Termination 6.5. By oncology therapy area 6.6. By monoclonal antibody type Chapter 7 -Partnering resource center Online partnering 7.2. Partnering events 7.3. Further reading on dealmaking Appendices Appendix 1 - Deal type definitions Appendix 2 - Example monoclonal antibody cancer partnering agreement About Wildwood Ventures Current Partnering Current Agreements Recent report titles from CurrentPartnering Order Form - Technology Reports Order Form - Therapy Reports Table of figures Companies mentioned Abbott Japan Abbott Laboratories Abraxis BioScience ACADIA Pharmaceuticals Acceleron Pharma Achillion Pharmaceuticals Adnexus Therapeutics Adolor AEterna Zentaris Affymax Agensys Alfacell Allergan Ambit Biosciences Amgen Amylin Pharmaceuticals Anacor Pharmaceuticals Anesiva Archemix Ariad Pharmaceuticals ArQule Array Biopharma ARYx Therapeutics Astellas Pharma AstraZeneca Athersys Atley Pharmaceuticals Auriga Laboratories Aventis AVEO Pharmaceuticals Barrier Therapeutics Bayer Biogen Idec BioMarin Pharmaceuticals BioMerieux Biovail Boehringer Ingelheim Bristol-Myers Squibb Cardiome Pharma Celgene Cell Genesys Cepheid ChemoCentryx Cornerstone Biopharma Cortex Pharmaceuticals Critical Therapeutics Cubist Pharmaceuticals CV Therapeutics Cypress Bioscience Cytokinetics Daiichi Sankyo DepoMed Dey Pharma DoctorDirectory DOR BioPharma Dyax Dynavax Technologies Eisai Eli Lilly Enanta Pharmaceuticals Endo Pharmaceuticals Exelixis Facet Biotechnology Forest Laboratories Forest Pharmaceuticals Galderma Genentech Genzyme Gilead Sciences GlaxoSmithKline Hyperion Therapeutics ImmunoGen Immunomedics Impax Laboratories Incyte Inspire Pharmaceuticals InterMune InVentiv Health Ipsen Ironwood Pharmaceuticals Janssen Research & Development KaloBios Pharmaceuticals La Jolla Pharmaceutical Macrogenics MAP Pharmaceuticals Maxygen Medivation Menarini Merck and Co Merck KGaA Merck Sharpe & Dohme Merrimack Pharmaceuticals Metabasis Therapeutics Micromet MiddleBrook Pharmaceutical Millennium Mylan Laboratories Nektar Therapeutics Novartis Novartis Consumer Health Novo Nordisk Nycomed OncoGenex Pharmaceuticals Optimer Pharmaceuticals Orexigen Therapeutics Ortho Biotech Par Pharmaceutical PDL BioPharma Pfizer PhotoMedex Procter & Gamble Procter & Gamble Pharmaceuticals Purdue Pharma Regeneron Pharmaceuticals Rib-X Pharmaceuticals Roche Sagent Pharmaceuticals Salix Pharmaceuticals Sanofi-Aventis Sanofi-Pasteur Sanofi Santarus Schering-Plough Seattle Genetics Serono Sigma-Tau Solvay Somaxon Pharmaceuticals Spectrum Pharmaceuticals Strativa Pharmaceuticals Sucampo Pharmaceuticals Synta Pharmaceuticals Takeda Pharmaceutical TAP Pharmaceutical Targacept Tercica Teva Pharmaceuticals Tibotec Transcept Pharmaceuticals Ucyclyd Pharma Valeant Pharmaceuticals Veracyte Vernalis Vical Victory Pharma Warner Chilcott Watson Pharmaceuticals Wyeth Xenoport Zogenix ZymoGenetics To order this report: Cancer Monoclonal Antibody Partnering Terms and Agreements http://www.reportlinker.com/p01112622/Cancer-Monoclonal-Antibody-Partnering-Terms-and-Agreements.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic